35. SEGMENTED INFORMATION

Reportable segments

The Company reports its financial results for the following four reportable segments:

Canada cannabis - includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis-related products in Canada pursuant to the Cannabis Act and cannabis-related areas such as merchandise and clinics;
International markets cannabis - includes the production, distribution and sale of a diverse range of cannabis and hemp products internationally pursuant to applicable international legislation, regulations and permits. Priority markets include medical cannabis in Australia and Europe where the Company offers branded high-quality flower, oil and extract products under the Company's recognized Spectrum Therapeutics and Canopy Medical brands, as well as the Company's Storz & Bickel line of medically approved vaporizers in Australia;
Storz & Bickel - includes the production, distribution and sale of vaporizers and accessories; and
This Works - includes the production, distribution and sale of beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker (“CODM”), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other".

The accounting policies of each segment are the same as those disclosed in the summary of significant accounting policies in Note 3.

 

 

Years ended

 

 

 

March 31,

 

 

March 31,

 

 

March 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Segmented net revenue

 

 

 

 

 

 

 

 

 

Canada cannabis1

 

$

155,860

 

 

$

159,165

 

 

$

195,445

 

International markets cannabis

 

 

39,734

 

 

 

41,312

 

 

 

38,949

 

Storz & Bickel

 

 

73,401

 

 

 

70,670

 

 

 

64,845

 

This Works

 

 

-

 

 

 

21,256

 

 

 

26,029

 

Other1

 

 

-

 

 

 

4,743

 

 

 

7,985

 

 

 

$

268,995

 

 

$

297,146

 

 

$

333,253

 

Segmented gross margin:

 

 

 

 

 

 

 

 

 

Canada cannabis2

 

$

36,517

 

 

$

25,640

 

 

$

(92,894

)

International markets cannabis

 

 

15,225

 

 

 

16,682

 

 

 

(3,322

)

Storz & Bickel

 

 

27,769

 

 

 

30,128

 

 

 

26,112

 

This Works

 

 

-

 

 

 

10,534

 

 

 

10,205

 

Other2

 

 

-

 

 

 

(2,102

)

 

 

(3,630

)

 

 

 

79,511

 

 

 

80,882

 

 

 

(63,529

)

Selling, general and administrative expenses

 

 

169,626

 

 

 

229,429

 

 

 

342,517

 

Share-based compensation

 

 

(4,205

)

 

 

14,180

 

 

 

25,322

 

Loss on asset impairment and restructuring

 

 

31,233

 

 

 

65,987

 

 

 

2,199,146

 

Operating loss from continuing operations

 

 

(117,143

)

 

 

(228,714

)

 

 

(2,630,514

)

Other income (expense), net

 

 

(479,854

)

 

 

(242,641

)

 

 

(455,644

)

Loss from continuing operations before incomes taxes

 

$

(596,997

)

 

$

(471,355

)

 

$

(3,086,158

)

1 A reclassification of $5,449 and $8,378 of ancillary cannabis revenues from Other to Canada cannabis occurred for the year ended March 31, 2024 and March 31, 2023, respectively.

2 A reclassification of $744 and $2,397 of ancillary cannabis gross margins from Other to Canada cannabis occurred for the year ended March 31, 2024 and March 31, 2023, respectively.

Asset information by segment is not provided to, or reviewed by, the Company’s CODM as it is not used to make strategic decisions, allocate resources, or assess performance.

Entity-wide disclosures

Disaggregation of net revenue by geographic area:

 

 

Years ended

 

 

 

March 31,

 

 

March 31,

 

 

March 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Canada

 

$

155,912

 

 

$

162,712

 

 

$

201,417

 

Germany

 

 

59,904

 

 

 

52,194

 

 

 

48,701

 

United States

 

 

35,990

 

 

 

40,988

 

 

 

36,431

 

Other

 

 

17,189

 

 

 

41,252

 

 

 

46,704

 

 

 

$

268,995

 

 

$

297,146

 

 

$

333,253

 

Disaggregation of long-lived tangible assets by geographic area:

 

 

March 31,

 

 

March 31,

 

 

 

2025

 

 

2024

 

Canada

 

$

239,382

 

 

$

266,086

 

Germany

 

 

53,079

 

 

 

50,527

 

Other

 

 

1,062

 

 

 

3,490

 

 

 

$

293,523

 

 

$

320,103

 

For the year ended March 31, 2025, one customer represented more than 10% of the Company’s net revenue (years ended March 31, 2024 and 2023, one and one, respectively).

Historical Timeline

Fiscal YearFiled
2025May 30, 2025Showing above
2024May 30, 2024
2023Jun 22, 2023
2022May 31, 2022
2021Jun 1, 2021
2020Jun 1, 2020

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.